2024
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original Research
2023
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2023, 189: k19-k24. PMID: 37952170, DOI: 10.1093/ejendo/lvad147.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Hyperplasia, CongenitalAdrenocorticotropic HormoneBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolFemaleGlucoseHumansHydrocortisoneHypoglycemiaConceptsClassical congenital adrenal hyperplasiaClassical CAHCongenital adrenal hyperplasiaContinuous glucose monitoringLower cortisol concentrationsGlucose patternsAdrenal hyperplasiaCortisol concentrationsGlucose monitoringFludrocortisone replacement therapySensor glucose valuesHydrocortisone doseAcute illnessAsymptomatic hypoglycemiaWhole cohortNighttime hypoglycemiaReplacement therapyPercentage of timeObservational studyGlucose profilesGlycemic patternsSerial measuresGlucose valuesDaily cortisolHypoglycemiaQuantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2023, 66: 2189-2199. PMID: 37712956, PMCID: PMC10627950, DOI: 10.1007/s00125-023-06011-5.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glucose Tolerance TestHumansInsulinInsulin ResistanceInsulin-Secreting CellsConceptsType 1 diabetesBeta-cell functionInsulin secretionFunctional beta-cell massEarly pre-symptomatic stagesCell functionPre-symptomatic phaseBeta-cell massDisease-modifying interventionsPre-symptomatic stageContinuous glucose monitoringIslet autoimmunityInsulin sensitivityDisease progressionGlucose profilesInvasive measuresPreclinical stageMetabolic testsProgressive lossDiabetesMetabolic changesGlucose monitoringAvailable testsMeasurable changesOGTTA New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes
Schiavon M, Galderisi A, Basu A, Kudva Y, Cengiz E, Man C. A New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 270-278. PMID: 36648253, PMCID: PMC10066780, DOI: 10.1089/dia.2022.0397.Peer-Reviewed Original Research
2022
Glucose variability increases during minimally invasive procedures in very preterm infants
Galderisi A, Res G, Guiducci S, Savio F, Brigadoi S, Forlani L, Mastrandrea B, Moschino L, Lolli E, Priante E, Trevisanuto D, Baraldi E. Glucose variability increases during minimally invasive procedures in very preterm infants. European Journal Of Pediatrics 2022, 182: 89-94. PMID: 36201017, PMCID: PMC9829573, DOI: 10.1007/s00431-022-04641-2.Peer-Reviewed Original ResearchMeSH KeywordsBirth WeightBlood GlucoseBlood Glucose Self-MonitoringGlucoseHumansInfant, NewbornInfant, PrematureInfant, Premature, DiseasesMinimally Invasive Surgical ProceduresConceptsVery preterm infantsContinuous glucose monitoringPreterm infantsGlucose variabilityNeonatal stressNappy changeInvasive proceduresMedian glucoseGlucose monitoringNon-invasive procedurePrimary outcomeAbsence of changesHeel prickMean glucoseNeonatal proceduresCare proceduresDay 2InfantsParental presenceGlucose variationCGM dataGlucoseSDNeonatesPrick
2020
Effect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugEquipment and SuppliesFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin Infusion SystemsInsulin, Regular, HumanMaleMealsPostprandial PeriodYoung AdultConceptsControl armPremeal bolusesPostprandial plasma glucose levelsPostprandial blood glucose controlPrimary efficacy outcomeRapid-acting insulinBlood glucose controlPlasma glucose levelsType 1 diabetesLater time pointsSequential mealsEfficacy outcomesPPG levelsSecondary outcomesGlycemic excursionsMeal studyGlucose controlSubcutaneous routeInsulin delivery systemsGlucose levelsGlucose metricsHigh doseStudy daysInsulin absorptionInsulin bolus
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdultsA Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A, Sherr JL. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals 2019, 48: e311-e318. PMID: 31426099, DOI: 10.3928/19382359-20190725-03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInfusion Pumps, ImplantableInsulinInsulin Infusion SystemsConceptsContinuous glucose monitoringType 1 diabetesGlycemic controlContinuous subcutaneous insulin infusion pumpClosed-loop insulin deliveryIntensive insulin treatmentMultiple daily injectionsChronic medical conditionsLoop insulin deliveryPediatric clinical practiceInsulin infusion pumpDaily injectionsBlood glucoseInsulin treatmentMedical conditionsDiabetes treatmentClinical practiceNew treatmentsGlucose monitoringInfusion pumpInsulin deliveryT1DDiabetesTreatmentSuspension device